위식도 역류질환 치료제 시장 : 치료법별, 제형별, 투여 경로별, 의약품 유형별, 약제 승인 상황별, 질환 중증도별, 유통 채널별, 최종 사용자별 예측(2026-2032년)

The Gastroesophageal Reflux Disease Therapeutics Market is projected to grow by USD 7.88 billion at a CAGR of 5.36% by 2032.

Executive Summary: Gastroesophageal Reflux Disease Therapeutics

Gastroesophageal reflux disease therapeutics address a chronic, relapsing condition characterized by reflux of gastric contents that causes troublesome heartburn, regurgitation, sleep disruption, reduced quality of life, and complications such as erosive esophagitis, peptic stricture, and Barrett's esophagus. Clinical guidance from the American College of Gastroenterology supports an empiric proton pump inhibitor trial for typical symptoms without alarm features, while endoscopy and reflux monitoring remain central for complicated, refractory, or diagnostically uncertain cases.

The market is anchored by widely used proton pump inhibitors, H2-receptor antagonists, antacids, alginates, prokinetics in selected settings, and newer potassium-competitive acid blockers. Demand is reinforced by obesity, aging populations, dietary patterns, OTC availability, and growing recognition of non-erosive reflux disease, making GERD therapeutics a high-volume category across prescription and consumer health channels.

Transformative Shifts Reshaping GERD Treatment

The GERD therapeutics landscape is shifting from symptom suppression alone toward precision diagnosis, mucosal healing, durable acid control, and long-term safety management. The 2020 FDA request to remove ranitidine products because of NDMA impurity concerns reshaped H2 blocker use and increased attention to pharmacovigilance, impurity testing, and supply-chain quality.

Innovation is also changing competitive dynamics. Potassium-competitive acid blockers, including vonoprazan, provide rapid and sustained acid suppression and have gained regulatory traction in major markets. At the same time, payers continue to favor low-cost generic PPIs, creating a market where differentiated therapies must prove clinical value in erosive esophagitis healing, symptom relief, adherence, and outcomes in PPI-inadequate responders.

Cumulative Impact of Artificial Intelligence in GERD Therapeutics

Artificial intelligence is beginning to influence GERD therapeutics across discovery, diagnosis, trial design, and real-world evidence. Machine learning can analyze endoscopy images, electronic health records, symptom diaries, pH-impedance datasets, and prescription patterns to identify patients with refractory symptoms, alarm features, adherence gaps, or potential drug-drug interaction risks.

The cumulative impact is operational as much as scientific. AI-enabled pharmacovigilance can detect safety signals earlier, while predictive analytics can support patient segmentation for PPIs, H2 blockers, alginates, PCABs, or procedural referral. For manufacturers and healthcare stakeholders, AI can shorten evidence generation cycles by improving site selection, patient recruitment, real-world outcomes assessment, health economic modeling, and post-launch performance tracking.

Key Regional Insights Across GERD Therapeutics

Asia-Pacific is a high-volume opportunity because of large patient populations, urban dietary changes, growing private healthcare use, and established acid-suppression prescribing, with Japan offering early clinical experience in potassium-competitive acid blockers and several countries expanding access to gastroenterology services. North America remains a premium market driven by high diagnosis rates, OTC and prescription availability, strong gastroenterology networks, FDA approvals, and significant payer scrutiny of differentiated therapies.

Latin America relies heavily on generics and retail pharmacy access, while Brazil and Mexico provide scale through large urban populations, expanding specialty care, and rising use of structured regulatory pathways. Europe combines strong guideline adoption, generic cost containment, and centralized or national health technology assessment, creating a disciplined environment for clinical evidence and reimbursement decisions. The Middle East, especially GCC markets, benefits from healthcare investment, insurance expansion, and high obesity prevalence, whereas Africa remains underdiagnosed, with access tied to affordable generics, diagnostic capacity, trained clinicians, and urban healthcare expansion.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets show uneven but rising demand, shaped by retail pharmacy access, hospital-based specialist care, and expanding middle-class healthcare spending in countries with different reimbursement maturity levels. The GCC is distinguished by high metabolic disease burden, insurance expansion, and investment in tertiary care, supporting demand for both established PPIs and premium therapies where reimbursement and formulary access are available.

The European Union emphasizes regulatory rigor, pharmacovigilance, generics, and health technology assessment, making evidence quality essential for GERD therapeutics. BRICS countries combine large patient pools with strong generic competition, local manufacturing priorities, and growing diagnostic infrastructure. G7 markets lead in clinical research, regulatory oversight, and branded innovation, while NATO should be viewed primarily as a supply-chain resilience and procurement continuity lens rather than a healthcare purchasing bloc, given its diverse national reimbursement systems and separate medicine access policies.

Key Country Insights for Priority GERD Markets

The United States leads commercialization through FDA pathways, OTC-to-prescription channel breadth, broad direct-to-consumer awareness, and rapid uptake of differentiated drugs when outcomes justify coverage. Canada emphasizes evidence-based reimbursement, while Mexico and Brazil are scale markets where COFEPRIS and ANVISA oversight, generic penetration, and private-sector access shape adoption. The United Kingdom, Germany, France, Italy, and Spain are mature European markets where NICE, AMNOG, HAS, and regional procurement frameworks influence pricing, prescribing, and formulary use.

Russia prioritizes domestic supply resilience and continued access to essential generics, while China and India combine large symptomatic populations with strong generic manufacturing, expanding gastroenterology capacity, and increasing use of endoscopy in urban centers. Japan is a benchmark for PCAB adoption, aging-related demand, and structured gastroenterology care. Australia's TGA and PBS frameworks support evidence-led access, and South Korea's NHIS environment, advanced endoscopy capacity, and strong hospital networks support structured diagnosis, monitoring, and treatment optimization.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated evidence over incremental positioning. Clinical programs should demonstrate healing rates, sustained symptom control, nighttime relief, adherence benefits, safety, and value in patients with inadequate response to standard PPIs. Real-world evidence should be built early to support payer discussions, treatment pathway inclusion, and guideline relevance.

Commercial teams should balance branded innovation with high-volume generic realities, invest in physician and pharmacist education, and segment patients by disease severity, diagnostic confirmation, alarm features, and treatment history. Supply-chain quality, impurity surveillance, responsible OTC communication, and digital adherence tools should be integrated into lifecycle strategy to protect trust, support appropriate use, and expand access.

Research Methodology

This executive summary is grounded in a structured review of clinical guidelines, regulatory communications, peer-reviewed literature, public health datasets, healthcare policy sources, and publicly available therapeutic class information. Core references include guidance from gastroenterology societies, FDA and EMA regulatory information, national reimbursement frameworks, and epidemiology inputs from recognized public health institutions.

Insights were triangulated across therapeutic class dynamics, patient pathways, reimbursement environments, regional healthcare capacity, regulatory trends, and technology adoption signals. The methodology emphasizes verified secondary research, consistency checks across authoritative sources, and market interpretation aligned with clinical practice rather than unsupported forecasting, market sizing, or market share claims.

Conclusion

GERD therapeutics remain a resilient and clinically essential category because reflux symptoms are common, recurrent, and often require long-term management. Generic PPIs continue to anchor treatment volume, but innovation is expanding around PCABs, optimized formulations, digital monitoring, and evidence-based treatment pathways for refractory or complicated disease.

The most successful stakeholders will align clinical differentiation with payer value, regulatory quality, patient adherence, and regional access realities. As AI, real-world evidence, and precision diagnosis mature, GERD therapeutics will move toward more targeted care models that improve symptom control, safety oversight, and resource efficiency.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gastroesophageal Reflux Disease Therapeutics Market, by Treatment Type

• 7.1. Pharmacologic Therapies
  • 7.1.1. Proton Pump Inhibitors (PPIs)
  • 7.1.2. H2 Receptor Antagonists
  • 7.1.3. Antacid
  • 7.1.4. Mucosal Coating Agent
    • 7.1.4.1. Sucralfate & Coating Agents
    • 7.1.4.2. Alginates/Raft Formers
• 7.2. Surgical Interventions
• 7.3. Device-Based Therapies

8. Gastroesophageal Reflux Disease Therapeutics Market, by Dosage Form

• 8.1. Capsule
• 8.2. Liquid
• 8.3. Suspension
• 8.4. Tablet

9. Gastroesophageal Reflux Disease Therapeutics Market, by Route Of Administration

• 9.1. Oral
• 9.2. Injectable

10. Gastroesophageal Reflux Disease Therapeutics Market, by Medicine Type

• 10.1. Over-The-Counter
• 10.2. Prescription

11. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Status

• 11.1. Branded
• 11.2. Generic

12. Gastroesophageal Reflux Disease Therapeutics Market, by Disease Severity

• 12.1. Mild
• 12.2. Moderate
• 12.3. Severe

13. Gastroesophageal Reflux Disease Therapeutics Market, by Distribution Channel

• 13.1. Hospital Pharmacies
• 13.2. Online Pharmacies
• 13.3. Retail Pharmacies

14. Gastroesophageal Reflux Disease Therapeutics Market, by End User

• 14.1. Home Care Settings
• 14.2. Hospitals
• 14.3. Specialty Clinics

15. Gastroesophageal Reflux Disease Therapeutics Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Gastroesophageal Reflux Disease Therapeutics Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Gastroesophageal Reflux Disease Therapeutics Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. AstraZeneca plc
• 19.2. Aurobindo Pharma Limited
• 19.3. Bayer AG
• 19.4. Cadila Pharmaceuticals Ltd.
• 19.5. Camber Pharmaceuticals, Inc.
• 19.6. Daewoong Pharmaceutical Co., Ltd.
• 19.7. Dr. Reddy's Laboratories Limited
• 19.8. Eisai Co., Ltd.
• 19.9. Elite Wealth Ltd.
• 19.10. Haleon plc
• 19.11. HK inno.N Co., Ltd.
• 19.12. Ironwood Pharmaceuticals, Inc.
• 19.13. Johnson & Johnson Services, Inc.
• 19.14. Lupin Limited
• 19.15. Onconic Therapeutics Inc.
• 19.16. Pfizer Inc.
• 19.17. Phathom Pharmaceuticals, Inc.
• 19.18. RaQualia Pharma Inc.
• 19.19. Reckitt Benckiser Group plc
• 19.20. Sandoz Group AG
• 19.21. Sanofi S.A.
• 19.22. Sebela Pharmaceuticals Inc.
• 19.23. Sun Pharmaceutical Industries Limited
• 19.24. Takeda Pharmaceutical Company Limited
• 19.25. Teva Pharmaceutical Industries Ltd.
• 19.26. The Procter & Gamble Company
• 19.27. Viatris Inc.